Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22209237 | 1.00 | GSR (0.48) | GSRKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL3909526 | 0.88 | GSR (0.50) | GSRDPP7DPP9DPP8GNAI3 | |
| SCHEMBL6562358 | 0.88 | GSR (0.50) | GSRDPP7DPP9DPP8GNAI3 | |
| SCHEMBL6562360 | 0.88 | GSR (0.50) | GSRDPP7DPP9DPP8GNAI3 | |
| SCHEMBL1168273 | 0.86 | GSR (0.42) | GSRMEN1KMT2ADPP7DPP9 | |
| SCHEMBL29073349 | 0.83 | KDM4E (0.59) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL29073213 | 0.83 | KDM4E (0.59) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL1168277 | 0.82 | GSR (0.44) | GSRLMNADPP7DPP9DPP8 | |
| SCHEMBL1168594 | 0.82 | GSR (0.44) | GSRLMNADPP7DPP9DPP8 | |
| SCHEMBL1167729 | 0.82 | GSR (0.44) | GSRLMNADPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230313204-A1 | ANTI-CHYMASE APTAMER AND USE FOR SAME | RIBOMIC INC. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230235333-A1 | APTAMER FOR IL-21 AND USE THEREOF | RIBOMIC INC. (JP) | 2023-07-27 | — | — | US | disclosed |
| US-11667935-B2 | Fermentation process for improved glycerol and acetic acid conversion | DSM IP ASSETS B.V. (NL) | 2023-06-06 | — | — | US | disclosed |
| US-11639503-B2 | Anti-chymase aptamer and use for same | RIBOMIC INC. (JP) | 2023-05-02 | — | — | US | disclosed |
| EP-4170030-A1 | APTAMER FOR IL-21 AND USE THEREOF | RIBOMIC INC. (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-11473089-B2 | Aptamer for ADAMTS5 and use for aptamer for ADAMTS5 | RIBOMIC INC. (JP) | 2022-10-18 | — | — | US | disclosed |
| US-20220282255-A1 | APTAMER FOR TGF-BETA1 AND USE OF SAME | RIBOMIC INC. (JP) | 2022-09-08 | — | — | US | disclosed |
| CN-114624362-A | Kit for detecting advanced glycosylation end products in serum and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2022-06-14 | — | — | CN | disclosed |
| EP-3908601-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Omeros Corporation (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3831950-A1 | FERMENTATION PROCESS WITH IMPROVED GLYCEROL AND ACETIC ACID CONVERSION | DSM IP Assets B.V. (NL) | 2021-06-09 | — | — | EP | disclosed |
| EP-3234161-B1 | FERMENTATION PROCESS WITH IMPROVED GLYCEROL AND ACETIC ACID CONVERSION | DSM IP ASSETS BV (NL) | 2021-03-17 | — | — | EP | disclosed |
| US-20210071205-A1 | FERMENTATION PROCESS FOR IMPROVED GLYCEROL AND ACETIC ACID CONVERSION | DSM IP ASSETS B.V. (NL) | 2021-03-11 | — | — | US | disclosed |
| US-10883122-B2 | Fermentation process for improved glycerol and acetic acid conversion | DSM IP ASSETS B.V. (NL) | 2021-01-05 | — | — | US | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| WO-2020146795-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| CN-111193069-A | Metal salt, method for preparing metal salt, and electrolyte and electrochemical device each containing metal salt | 三星电子株式会社 | 2020-05-22 | — | — | CN | disclosed |
| CN-109112169-A | Polylysine glyceride and preparation method thereof, purposes and the method for preparing polylysine | 武汉臻智生物科技有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20170335350-A1 | FERMENTATION PROCESS FOR IMPROVED GLYCEROL AND ACETIC ACID CONVERSION | DSM IP ASSETS B.V. (NL) | 2017-11-23 | — | — | US | disclosed |
| EP-3234161-A1 | FERMENTATION PROCESS WITH IMPROVED GLYCEROL AND ACETIC ACID CONVERSION | DSM IP Assets B.V. (NL) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097202-A1 | FERMENTATION PROCESS WITH IMPROVED GLYCEROL AND ACETIC ACID CONVERSION | DSM IP ASSETS B.V. (NL) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230313204-A1 | ANTI-CHYMASE APTAMER AND USE FOR SAME | RNASE1, CPA1, RNASEH1 | GSR 4435/4885KDM4E 4725/4885DUSP3 3862/4885 |
| US-11639503-B2 | Anti-chymase aptamer and use for same | RNASE1, CPA1, RNASEH1 | GSR 4435/4885KDM4E 4725/4885DUSP3 3862/4885 |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | LPAR5, LPAR3, LPAR1 | GSR 425/4885KDM4E 3685/4885DUSP3 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.